Clinical Trial Update: A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) [Phase 3]

View source ↗

Summary

Phase 3 study to assess long-term safety and effects of felzartamab infusions in adults with antibody-mediated rejection after kidney transplantation; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Kidney Transplant Rejection

Drugs mentioned

• Felzartamab (felzartamab)

Snippet

Sponsor: Biogen | Conditions: Antibody-mediated Rejection | Phase 3 | Status: NOT_YET_RECRUITING